Literature DB >> 30712228

Direct antimicrobial susceptibility testing from the blood culture pellet obtained for MALDI-TOF identification of Enterobacterales and Pseudomonas aeruginosa.

J M López-Pintor1, C Navarro-San Francisco2,3, J Sánchez-López1, A García-Caballero1, E Loza Fernández de Bobadilla1,4, M I Morosini1,4, R Cantón1,4.   

Abstract

To standardize the methodology for conducting direct antimicrobial susceptibility testing (AST) of Enterobacterales and Pseudomonas aeruginosa causing bacteremia from positive blood culture pellets. Two methods for processing positive blood cultures with Enterobacterales and P. aeruginosa were compared: a conventional method for identification and AST versus a direct method obtaining a pellet for both matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) identification and direct AST. A total of 157 (145 Enterobacterales, 12 P. aeruginosa) positive blood cultures were included. Microorganism identification showed 100% concordance between both methods at species and genus level. Definitive AST results were obtained 24 h earlier with the rapid method than the conventional one (p < 0.001). Of the 2814 MICs generated, there were discrepancies with respect to the conventional method in 47 (1.7%), 0.3% being very major (VME) and 1.3% major (ME) errors. Better results for AST were obtained when colony counts with the pellet were ≥ 105 cfu/ml. The essential agreement (EA) for antibiotics tested in Enterobacterales was at least 97%, except for ampicillin (95%). Regardless of colony count, the greatest discrepancies were observed for first/s-generation cephalosporins and aminoglycosides. In P. aeruginosa, EA was at least 92%, except for piperacillin-tazobactam (84%) and cefepime (76%). No VME occurred except for ceftazidime (8%). ME occurred in piperacillin/tazobactam (16%), ticarcillin, ceftazidime, tobramycin, amikacin, and colistin (8% each). Direct use of the blood culture pellet permits fast AST in bacteremia of Enterobacterales, enabling the clinicians to perform an early treatment adjustment. However, for Pseudomonas aeruginosa, the data needs expanding to improve the reliability of this technique.

Entities:  

Keywords:  Bacteraemia; Blood culture pellet; Direct antimicrobial susceptibility testing; Gram-negative bacilli; MALDI-TOF

Mesh:

Substances:

Year:  2019        PMID: 30712228     DOI: 10.1007/s10096-019-03498-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  Evaluation of wider system for direct identification and antimicrobial susceptibility testing of gram-negative bacilli from positive blood culture bottles.

Authors:  D Fontanals; F Salceda; J Hernández; I Sanfeliu; M Torra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-09-10       Impact factor: 3.267

2.  Use of positive blood cultures for direct identification and susceptibility testing with the vitek 2 system.

Authors:  Marina de Cueto; Esther Ceballos; Luis Martinez-Martinez; Evelio J Perea; Alvaro Pascual
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  A simple blood-culture bacterial pellet preparation for faster accurate direct bacterial identification and antibiotic susceptibility testing with the VITEK 2 system.

Authors:  Guy Prod'hom; Christian Durussel; Gilbert Greub
Journal:  J Med Microbiol       Date:  2013-01-17       Impact factor: 2.472

4.  Automated alerts coupled with antimicrobial stewardship intervention lead to decreases in length of stay in patients with gram-negative bacteremia.

Authors:  Jason M Pogue; Ryan P Mynatt; Dror Marchaim; Jing J Zhao; Viktorija O Barr; Judy Moshos; Bharath Sunkara; Teena Chopra; Sowmya Chidurala; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2013-12-24       Impact factor: 3.254

5.  The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.

Authors:  E H Ibrahim; G Sherman; S Ward; V J Fraser; M H Kollef
Journal:  Chest       Date:  2000-07       Impact factor: 9.410

6.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

7.  Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use.

Authors:  J J Kerremans; P Verboom; T Stijnen; L Hakkaart-van Roijen; W Goessens; H A Verbrugh; M C Vos
Journal:  J Antimicrob Chemother       Date:  2007-12-21       Impact factor: 5.790

8.  Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia.

Authors:  Angela M Huang; Duane Newton; Anjly Kunapuli; Tejal N Gandhi; Laraine L Washer; Jacqueline Isip; Curtis D Collins; Jerod L Nagel
Journal:  Clin Infect Dis       Date:  2013-07-29       Impact factor: 9.079

9.  Identification and susceptibility testing of Enterobacteriaceae and Pseudomonas aeruginosa by direct inoculation from positive BACTEC blood culture bottles into Vitek 2.

Authors:  Marjan J Bruins; Peter Bloembergen; Gijs J H M Ruijs; Maurice J H M Wolfhagen
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

Review 10.  Using rapid diagnostic tests to optimize antimicrobial selection in antimicrobial stewardship programs.

Authors:  Debra A Goff; Christopher Jankowski; Fred C Tenover
Journal:  Pharmacotherapy       Date:  2012-08       Impact factor: 4.705

View more
  2 in total

1.  Direct Rapid Identification from Positive Blood Cultures by MALDI-TOF MS: Specific Focus on Turnaround Times.

Authors:  Hazan Zengin Canalp; Banu Bayraktar
Journal:  Microbiol Spectr       Date:  2021-12-15

2.  Real Life Clinical Impact of Antimicrobial Stewardship Actions on the Blood Culture Workflow from a Microbiology Laboratory.

Authors:  Jose Maria López-Pintor; Javier Sánchez-López; Carolina Navarro-San Francisco; Ana Maria Sánchez-Díaz; Elena Loza; Rafael Cantón
Journal:  Antibiotics (Basel)       Date:  2021-12-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.